Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Orally Effective CDK9 Inhibitor YX0798 for Treating Aggressive Lymphoma

Vivian Jiang, Yu Xue, Hong Kim, Qingsong Cai, Tianci Zhang, Lei Nie, Joseph McIntosh, Yang Liu, Haiyan Chen, David Santos, Selvi Thirumurthi, Jia Zhou, Michael Wang

Blood (2024) 144 (Supplement 1): 7474.

https://doi.org/10.1182/blood-2024-207657

Published: 2024

Journal Articles

The Reversible BTK Inhibitor Nemtabrutinib Demonstrates Favorable Antitumor Efficacy and Enhances the Function of CAR T Cells in Mantle Cell Lymphoma

Margaret Elizabeth Simmons, Joseph McIntosh, Tianci Zhang, Yijing Li, Fangfang Yan, Yixin Yao, Lei Nie, Heng-Huan Lee, Wei Wang, Vivian Changying Jiang, Michael Wang, Yang Liu

Blood (2023) 142 (Supplement 1): 5789.

https://doi.org/10.1182/blood-2023-187405

Published: 2023

Journal Articles

The Selective CDK9 Inhibitor VIP152 Overcame Therapeutic Resistance in Mantle Cell Lymphoma

William Lee, Vivian Changying Jiang, Tianci Zhang, Fangfang Yan, Qingsong Cai, Joseph McIntosh, Yang Liu, Michael L. Wang

Blood (2023) 142 (Supplement 1): 2821.

https://doi.org/10.1182/blood-2023-175035

Published: 2023

Journal Articles

Dual Targeting of ROR1 and BTK Augments the Anti-Lymphoma Activity in Mantle Cell Lymphoma

Lei Nie, Vivian Changying Jiang, Yang Liu, Joseph McIntosh, Jovanny Vargas, Qingsong Cai, Michael L. Wang

Blood (2023) 142 (Supplement 1): 4366.

https://doi.org/10.1182/blood-2023-189531

Published: 2023

Journal Articles

Establishment of a Patient-Derived Organoid Culture Platform for Mantle Cell Lymphoma Drug Sensitivity and CAR T Cell Anti-Tumor Activity Assay

Lei Nie, Yang Liu, Changying Jiang, Yuxuan Che, Jingling Jin, Qingsong Cai, Wei Wang, Yijing Li, Alexa A Jordan, Joseph McIntosh, Jovanny Vargas, Yixin Yao, Heng-Huan Lee, Michael L. Wang

Blood (2022) 140 (Supplement 1): 9219–9220.

https://doi.org/10.1182/blood-2022-169622

Published: 2022

Journal Articles

Modulating Immunometabolism to Reinvigorate T-Cell Effector Function and Antitumor Immunity in the Mantle Cell Lymphoma Microenvironment

Yixin Yao, Yang Liu, Yuxuan Che, Yijing Li, Heng-Huan Lee, Michael L. Wang, Joseph McIntosh

Blood (2022) 140 (Supplement 1): 6446–6447.

https://doi.org/10.1182/blood-2022-169543

Published: 2022

Journal Articles

HSP27 Promotes Mantle Cell Lymphoma Growth and Mediates Resistance to Venetoclax

Yuxuan Che, Wei Wang, Yang Liu, Heng-Huan Lee, Yijing Li, Zhihong Chen, Joseph McIntosh, Changying Jiang, Yixin Yao, Michael Wang

Blood (2022) 140 (Supplement 1): 6405–6406.

https://doi.org/10.1182/blood-2022-167611

Published: 2022

Journal Articles

Targeting the HSP90-MYC-CDK9 Axis to Overcome Dual Resistance to BTK Inhibition and CAR-T Therapy in Mantle Cell Lymphoma

Vivian Changying Jiang, Fangfang Yan, Alexa A Jordan, Yuxuan Che, Yang Liu, Qingsong Cai, Yijing Li, Joseph McIntosh, Zhihong Chen, Jovanny Vargas, Yixin Yao, Heng-Huan Lee, Jingling Jin, Wei Wang, Lei Nie, Zhongming Zhao, Lukas M Simon, Michael L. Wang

Blood (2022) 140 (Supplement 1): 3512–3513.

https://doi.org/10.1182/blood-2022-163696

Published: 2022

Journal Articles

Abemaciclib in Combination with Copanlisib to Overcome Therapeutic Resistance in Mantle Cell Lymphoma

Yuxuan Che, Yang Liu, Yijing Li, Joseph McIntosh, Alexa A Jordan, Zhihong Chen, Fangfang Yan, Wei Wang, Jingling Jin, Changying Jiang, Yixin Yao, Michael Wang

Blood (2021) 138 (Supplement 1): 2253.

https://doi.org/10.1182/blood-2021-150942

Published: 2021

Journal Articles

Establishment of Patient-Derived Organoid Culture Platform of Mantle Cell Lymphoma

Lei Nie, Yang Liu, Yuxuan Che, Yijing Li, Wei Wang, Jingling Jin, Qingsong Cai, Jovanny Vargas, Joseph McIntosh, Alexa A Jordan, Vivian Changying Jiang, Yixin Yao, Michael Wang

Blood (2021) 138 (Supplement 1): 3508.

https://doi.org/10.1182/blood-2021-152994

Published: 2021

Journal Articles

Dynamic Reprogramming and Evolution Associated with Sequential Resistance to Ibrutinib and CAR T Therapy in Mantle Cell Lymphoma

Fangfang Yan, Changying Jiang, Qingsong Cai, Preetesh Jain, Yijing Li, Yang Liu, Joseph McIntosh, Alexa A Jordan, Zhongming Zhao, Lukas Simon, Michael Wang

Blood (2021) 138 (Supplement 1): 2396.

https://doi.org/10.1182/blood-2021-149214

Published: 2021

Journal Articles

Single Cell Transcriptomic Profiling of Patient-Derived Xenografts of Mantle Cell Lymphoma Reveals a Special Tumor Cell Population: Seed Cells for Disease Dissemination and Progression

Vivian Changying Jiang, Qingsong Cai, Dapeng Hao, Yang Liu, Yijing Li, Yuxuan Che, Joseph McIntosh, Alexa A Jordan, Zhihong Chen, Angela Leeming, Lei Nie, Linghua Wang, Michael Wang

Blood (2021) 138 (Supplement 1): 1319.

https://doi.org/10.1182/blood-2021-149280

Published: 2021

Journal Articles

Bispecific CD19-CD20 and CD19-CD22 CAR-T Cells with Glycogen Synthase Kinase (GSK)-3β Inhibitor TWS119 Treatment Have Superior Therapeutic Effects on Mantle Cell Lymphoma

Jingling Jin, Yijing Li, Yang Liu, Alexa A Jordan, Joseph McIntosh, Jovanny Vargas, Yuxuan Che, Yixin Yao, Michael Wang

Blood (2021) 138 (Supplement 1): 1698.

https://doi.org/10.1182/blood-2021-150000

Published: 2021

Journal Articles

Combination Therapy of Bcl-2/X L dual Inhibitor AZD0466 with Acalabrutinib to Overcome Therapeutic Resistance in Aggressive R/R Mantle Cell Lymphoma

Yijing Li, Yang Liu, Yuxuan Che, Joseph McIntosh, Alexa A Jordan, Angela Leeming, Courtney L Andersen, Justin Cidado, Jingling Jin, Vivian Changying Jiang, Michael Wang

Blood (2021) 138 (Supplement 1): 1867.

https://doi.org/10.1182/blood-2021-151609

Published: 2021

Journal Articles

Pirtobrutinib Overcomes Ibrutinib and Venetoclax Resistance in Mantle Cell Lymphoma

Yang Liu, Changying Jiang, Fangfang Yan, Joseph McIntosh, Alexa A Jordan, Yijing Li, Yuxuan Che, Qingsong Cai, Wei Wang, Lei Nie, Michael Wang

Blood (2021) 138 (Supplement 1): 1182.

https://doi.org/10.1182/blood-2021-151401

Published: 2021

Journal Articles

Dual Targeting Bcl-2 By Venetoclax and Mcl-1 By AZD5991 to Overcome Therapeutic Resistance in Aggressive R/R Mantle Cell Lymphoma

Yijing Li, Yang Liu, Yuxuan Che, Alexa A Jordan, Joseph McIntosh, Angela Leeming, Courtney L Andersen, Justin Cidado, Jingling Jin, Vivian Changying Jiang, Michael Wang

Blood (2021) 138 (Supplement 1): 1181.

https://doi.org/10.1182/blood-2021-151062

Published: 2021

Journal Articles

Interrogation of Dysregulated Pathways Enables Precision Medicine in Mantle Cell Lymphoma

Yang Liu, PhD, Shuangtao Zhao, PhD, Changying Changying Jiang, PhD, Yixin Yao, PhD, Joseph McIntosh, BS, Alexa A Jordan, BS, Yijing Li, MS, Yuxuan Che, Preetesh Jain, MBBS,MDDM,PhD, Linghua Wang, PhD, Michael Wang, MD

Blood (2020) 136 (Supplement 1): 33.

https://doi.org/10.1182/blood-2020-140794

Published: 2020

Journal Articles

Abemaciclib-Based Combinational Therapies to Overcome Therapeutic Resistance in Mantle Cell Lymphoma

Yuxuan Che, Yang Liu, PhD, Lingzhi Li, Holly Hill, Joseph McIntosh, BS, Alexa A Jordan, BS, Dayoung Jung, Yixin Yao, PhD, Vivian Changying Jiang, PhD, Michael Wang, MD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-140856

Published: 2020

Journal Articles

Targeting the Synthetic Lethality Interaction of MTAP and PRMT5 to Overcome Drug Resistance and Enhance Anti-Cancer Immunity in Mantle Cell Lymphoma

Yixin Yao, PhD, Lingzhi Li, Yuxuan Che, Joseph McIntosh, BS, Holly Hill, Yang Liu, PhD, Michael Wang, MD

Blood (2020) 136 (Supplement 1): 15.

https://doi.org/10.1182/blood-2020-138553

Published: 2020

Journal Articles

Targeting ROR1 Using the Antibody Drug Conjugate Vls-101 in Aggressive Mantle Cell Lymphoma

Vivian Changying Jiang, PhD, Yang Liu, PhD, Joseph McIntosh, BS, Alexa A Jordan, BS, Angela Leeming, Zhihong Chen, Katti A. Jessen, PhD, Brian J. Lannutti, PhD, Michael Wang, MD

Blood (2020) 136 (Supplement 1): 33.

https://doi.org/10.1182/blood-2020-137660

Published: 2020

NARROW

Orally Effective CDK9 Inhibitor YX0798 for Treating Aggressive Lymphoma

The Reversible BTK Inhibitor Nemtabrutinib Demonstrates Favorable Antitumor Efficacy and Enhances the Function of CAR T Cells in Mantle Cell Lymphoma

The Selective CDK9 Inhibitor VIP152 Overcame Therapeutic Resistance in Mantle Cell Lymphoma

Dual Targeting of ROR1 and BTK Augments the Anti-Lymphoma Activity in Mantle Cell Lymphoma

Establishment of a Patient-Derived Organoid Culture Platform for Mantle Cell Lymphoma Drug Sensitivity and CAR T Cell Anti-Tumor Activity Assay

Modulating Immunometabolism to Reinvigorate T-Cell Effector Function and Antitumor Immunity in the Mantle Cell Lymphoma Microenvironment

HSP27 Promotes Mantle Cell Lymphoma Growth and Mediates Resistance to Venetoclax

Targeting the HSP90-MYC-CDK9 Axis to Overcome Dual Resistance to BTK Inhibition and CAR-T Therapy in Mantle Cell Lymphoma

Abemaciclib in Combination with Copanlisib to Overcome Therapeutic Resistance in Mantle Cell Lymphoma

Establishment of Patient-Derived Organoid Culture Platform of Mantle Cell Lymphoma

Dynamic Reprogramming and Evolution Associated with Sequential Resistance to Ibrutinib and CAR T Therapy in Mantle Cell Lymphoma

Single Cell Transcriptomic Profiling of Patient-Derived Xenografts of Mantle Cell Lymphoma Reveals a Special Tumor Cell Population: Seed Cells for Disease Dissemination and Progression

Bispecific CD19-CD20 and CD19-CD22 CAR-T Cells with Glycogen Synthase Kinase (GSK)-3β Inhibitor TWS119 Treatment Have Superior Therapeutic Effects on Mantle Cell Lymphoma

Combination Therapy of Bcl-2/X L dual Inhibitor AZD0466 with Acalabrutinib to Overcome Therapeutic Resistance in Aggressive R/R Mantle Cell Lymphoma

Pirtobrutinib Overcomes Ibrutinib and Venetoclax Resistance in Mantle Cell Lymphoma

Dual Targeting Bcl-2 By Venetoclax and Mcl-1 By AZD5991 to Overcome Therapeutic Resistance in Aggressive R/R Mantle Cell Lymphoma

Interrogation of Dysregulated Pathways Enables Precision Medicine in Mantle Cell Lymphoma

Abemaciclib-Based Combinational Therapies to Overcome Therapeutic Resistance in Mantle Cell Lymphoma

Targeting the Synthetic Lethality Interaction of MTAP and PRMT5 to Overcome Drug Resistance and Enhance Anti-Cancer Immunity in Mantle Cell Lymphoma

Targeting ROR1 Using the Antibody Drug Conjugate Vls-101 in Aggressive Mantle Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only